慢性基础肝病对新型冠状病毒肺炎患者结局的影响*

doi:10.3969/j.issn.1672-5069.2022.06.037

摘要/Abstract

摘要： 目的目前,由严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)感染导致的新型冠状病毒肺炎(COVID-19)仍在全球肆虐,成为国际关注的卫生公共事件。报道显示约2%～11%SARS-CoV-2感染患者患有慢性肝病基础,可出现不同程度的肝脏生化学异常。然而,SARS-CoV-2感染是否加重慢性肝病人群肝功能恶化导致慢加急性肝衰竭或急性肝功能失代偿等事件,仍有待于深入研究。本综述讨论了不同慢性肝病人群感染COVID-19的临床病程和预后情况,为临床治疗提供参考。

关键词: 新型冠状病毒肺炎, 慢性肝病, 肝损伤, 预后

Abstract: Objective Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection leads to a new type of coronavirus disease (COVID-19), which is still rampant in the world. It is reported that about 2% to 11% of SARS-CoV-2 infected patients have underlying chronic liver disease, and the impact of liver diseases on the susceptibility and severity of patients with COVID-19 infection, and whether the SARS-CoV-2 infection will deteriorate the progression of chronic liver diseases is still unclear. In this article, we mainly focus on the influence of different basic liver diseases on the outcomes of patients with COVID-19 infection.

Key words: Coronavirus disease 2019, Chronic liver disease, Liver injury, Prognosis

崔坡, 董士铭, 南月敏. 慢性基础肝病对新型冠状病毒肺炎患者结局的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 905-908.

Cui Po, Dong Shiming, Nan Yuemin. Prognosis of COVID-19 patients with underlying chronic liver diseases[J]. Journal of Practical Hepatology, 2022, 25(6): 905-908.

参考文献

[1] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges.Lancet Gastroenterol Hepatol, 2020, 5: 428-430.
[2] Guan WJ, Ni ZY, Hu Y,et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18):1708-1720.
[3] 胡利琳, 王玮珺, 朱清静, 等. 新型冠状病毒肺炎相关肝损伤:病因分析及治疗策略. 中华肝脏病杂志, 2020,25(2): 97-99.
[4] Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol,2020, 33(6):1007-1014.
[5] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8(4):420-422.
[6] Lei F, Liu YM, Zhou F, et al. Longitudinalassociation between markers of liver injury and mortality in COVID-19 in China. Hepatology, 2020, 72: 389-398.
[7] Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study. Hepatol Int, 2020, 14: 690-700.
[8] Marjot T, Webb GJ, Barritt ASt, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol, 2020, 18: 348-364.
[9] Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med, 2020, 382: 2137-2145.
[10] Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol, 2021, 74: 567-577.
[11] Satapathy SK, Roth NC, Kvasnovsky C, et al. Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study. Hepatol Int, 2021,15:300-304.
[12] Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut, 2021, 70: 531-536.
[13] Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol, 2021, 73: 1063-1071.
[14] Liu R, Zhao L, Cheng X, et al. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int, 2021, 41: 720-730.
[15] Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212: 416-420.
[16] Lens S, Miquel M, Mateos-Munoz B, et al. SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. J Hepatol, 2020, 73: 1262-1263.
[17] Elfiky AA. Ribavirin,remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci, 2020, 253: 117592.
[18] Chen L, Huang S, Yang J, et al. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. J Viral Hepat, 2020, 27: 1504-1507.
[19] Lin Y, Yuan J, Long Q, et al. Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. GeneDis, 2021, 8: 484-492.
[20] Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. World J Gastroenterol, 2021, 27: 782-793.
[21] Zou X, Fang M, Li S, et al. Characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Clin Gastroenterol Hepatol, 2021, 19: 597-603.
[22] Wong GL, Wong VW, Yuen BW, et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol, 2020, 72: 57-66.
[23] Liu J, Wang T, Cai Q, et al. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol Res, 2020, 50: 1211-1221.
[24] Rodriguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat, 2021, 28: 89-94.
[25] Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep, 2020, 2: 100113.
[26] Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology, 2020, 72: 287-304.
[27] Force AC-T, Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int, 2020, 14: 415-428.
[28] Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol, 2020, 73: 451-453.
[29] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181: 271-280,e278.
[30] Singh MK, Mobeen A, Chandra A, et al. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med, 2020, 130: 104219.
[31] Fondevila MF, Mercado-Gómez M, Rodríguez A, et al. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. J Hepatol, 2021, 74: 469-471.
[32] Zheng KI, Gao F, Wang XB, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism, 2020, 108: 154244.
[33] Dongiovanni P, Meroni M, Longo M, et al. MAFLD in COVID-19 patients: an insidious enemy. Expert Rev Gastroenterol Hepatol, 2020, 14: 867-872.
[34] Portincasa P, Krawczyk M, Smyk W, et al. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest, 2020, 50: e13338.
[35] Praveen S, Ashish K, Anikhindi SA, et al. Effect of COVID-19 on pre-existing liver disease: What Hepatologist should know? J Clin Exp Hepatol, 2020,35:124-128.
[36] Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut, 2020, 69: 1545-1547.
[37] Roca-Fernández A, Dennis A, Nicholls R, et al. Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19. Front Med, 2021, 8: 636637.
[38] Campos-Murguia A, Roman-Calleja BM, Toledo-Coronado IV, et al. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis, 2021,85:282-291.
[39] Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int, 2020, 40: 2568.
[40] Di Giorgio A, Nicastro E, Speziani C, et al. Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. J Hepatol, 2020, 73: 702-705.
[41] Verhelst X, Somers N, Geerts A, et al. Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. J Hepatol, 2021, 74: 240-241.
[42] Marjot T, Buescher G, Sebode M, et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol, 2021,15:327-330.
[43] Efe C, Dhanasekaran R, Lammert C, et al. Outcome of COVID-19 in patients with autoimmune hepatitis: an international multi-centre study. Hepatology, 2021,45:123-127.
[44] Sung H, Ferlay J, Siegel RL, et al. Globalcancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
[45] Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol, 2020, 21: 335-337.
[46] 易滨, 张磊, 袁振刚, 等. 新型冠状病毒肺炎疫情下肝癌的诊断与治疗策略. 肝胆外科杂志, 2020, 28(3): 208-212.

慢性基础肝病对新型冠状病毒肺炎患者结局的影响^*

Prognosis of COVID-19 patients with underlying chronic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵资德, 吴令杰, 张海生, 陈瑞烈. 纠正低蛋白血症减少抗结核药物性肝损伤发生临床研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 792-795.
[2]	李荣, 曹晶晶, 李晶, 潘峰. 慢加急性/亚急性乙型肝炎肝衰竭患者发病诱因及影响临床转归因素分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 832-835.
[3]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.
[4]	石青春, 潘立民, 布凡, 王永强, 关睿骞. 基于TCGA研究细胞坏死相关基因对肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 869-872.
[5]	高正兴, 李广欣, 宋春青. 癌组织M6A甲基转移酶样蛋白3水平对手术切除后接受索拉非尼治疗的肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 885-888.
[6]	付荣, 吴康卉, 石翠翠, 范建高, 李光明. BET选择性抑制剂38号化合物对急性肝损伤小鼠保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 620-623.
[7]	王倩, 李文莉, 王兵, 吴茂盛, 魏芳芳. 70例登革热并发肝损伤患者临床特征和预后因素分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 645-648.
[8]	刘艳, 沈宇, 张茜. 60例药物性肝损伤患者临床特征和转归分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 649-652.
[9]	王明强, 牛垚飞, 王生锋. 慢加急性乙型肝炎肝衰竭患者血清聚集素水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 677-680.
[10]	吴桐, 张巧丽, 齐雪维. 肝细胞癌RNA结合蛋白功能和预后价值系统分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 693-697.
[11]	蒋丽娜, 田晖, 苑志军, 张莉. 胆囊癌患者血管内皮生长因子C水平变化及其对手术治疗后预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(5): 746-749.
[12]	章思懿, 施军平. 重视内分泌系统疾病造成的肝损伤[J]. 实用肝脏病杂志, 2022, 25(4): 457-459.
[13]	刘海涛, 张雷鸣, 李经纬. 药物性肝损伤患者临床与病理学特征分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 508-511.
[14]	付丽红, 高月求, 王晓琳, 刘坤, 李曼, 黄凌鹰. 38例药物性肝损伤患者肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 512-516.
[15]	张岚, 李妍, 杨宁, 荆晶, 刘爱霞, 黄雨欣, 李伯安. 红细胞分布宽度和中性粒细胞/淋巴细胞比值评估原发性胆汁性胆管炎患者肝损伤临床价值研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 367-370.